Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

VACH

Voyager Acquisition Corp

May 28 • 12:27PM ET

10.17

+0.16 1.60 %

Financial • Shell Companies • USA • Small • NASD

May 26, 2:01 PMUltra-low float from 99.67% redemptions drives VACH's 18% surge on thin volume

Held by: CUSD

Scroll to Statements

Index	-	P/E	47.48	EPS (ttm)	0.21	Insider Own	-	Shs Outstand	31.62M	Perf Week	-7.63%
Market Cap	321.63M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	25.30M	Perf Month	-20.79%
Enterprise Value	321.60M	PEG	-	EPS next Q	-	Inst Own	49.68%	Short Float	0.01%	Perf Quarter	-4.60%
Income	6.74M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.09	Perf Half Y	-3.42%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	2.52%	Short Interest	0.00M	Perf YTD	-4.69%
Book/sh	-2.25	P/C	10721.00	EPS next 5Y	-	ROE	5.72%	52W High	15.68 -35.14%	Perf Year	-1.36%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	8.40 21.07%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	20.33% 15.89%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	2.24%	Oper. Margin	-	ATR (14)	1.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.00	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.91	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.00	EPS Q/Q	-91.03%	SMA20	-10.26%	Beta	-0.30	Target Price	-
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-	SMA50	-14.01%	Rel Volume	0.05	Prev Close	10.01
Employees	3	LT Debt/Eq	-	Earnings	-	SMA200	-6.53%	Avg Volume	18.83K	Price	10.17
IPO	Sep 30, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	455	Change	1.60%

Mar-13-26 06:00AM	Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG (GlobeNewswire)
Mar-11-26 06:00AM	Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG (GlobeNewswire) +14.68%
Jul-17-25 08:55AM	VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC (GlobeNewswire)
May-29-25 06:34PM	VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform (GlobeNewswire)
May-20-25 12:10PM	VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer (GlobeNewswire)
12:59PM	Loading…
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
Apr-23-25 01:09AM	VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies (GlobeNewswire)

Voyager Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on December 19, 2023 and is headquartered in Brooklyn, NY.

PresidentMr. Adeel Rouf Ennis

Chief Financial OfficerMr. Alex R. Rogers

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VACH

Voyager Acquisition Corp

Upgrade your Finviz experience